Medtronic Initiates Worldwide Pivotal Study to Evaluate its Extravascular Implantable Cardioverter Defibrillator System
Shots:
- Medtronic initiates global pivotal study evaluating its EV ICD system to treat dangerously fast heart rhythms in 400 patients at 60 sites across North America- Europe- the Middle East- Asia- Australia and New Zealand with the 1EPs as defibrillation testing success rate at the implant
- The EV ICD pivotal study follows the chronic EV ICD pilot study- evaluated 21 patients in New Zealand and Australia and early research and acute feasibility studies including the ASD- SPACE & ASD2
- The EV ICD system is designed to deliver lifesaving defibrillation and pacing therapy via a device the same size as traditional- transvenous ICDs- but with a lead (thin wire) placed outside the heart and veins
Click here to read full press release/ article | Ref: Medtronics | Image: Waterfall City
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com